 SAN CARLOS, Calif., Dec. 01, 2020 GLOBE NEWSWIRE -- BioCardia, Inc. Nasdaq: BCDA today announced that the Companys proprietary Helix Biotherapeutic Delivery System the Helix System demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, Cardiovascular Revascularization Medicine. The Helix System is being used in the pivotal Phase III CardiAMP Heart Failure Trial currently enrolling nationwide for infusion of BioCardias CardiAMP cell therapy to the myocardium. 